Corona Remedies’ sharp turnaround of the Myoril pain management brand into a nearly three-fold growth engine, accompanied by a major margin boost, stands out as the company’s strongest proof of execution ahead of its ₹655-crore IPO.

Nirav Mehta, Promoter, MD & CEO of Corona Remedies Limited, said the brand, acquired from Sanofi in 2022-23 (FY23), has grown from about ₹27–28 crore in annual sales to a targeted ₹90 crore-plus in two years, while delivering an 800-basis-point improvement in gross margins. “We have acquired that brand and given justice to that brand,” Mehta said, calling Myoril a perfect strategic fit that also gave the company a strong entry into pain management.

Corona Remedies is an India-focused branded pharmaceutical formulation company engaged in developing, manufact

See Full Page